AbbVie PE Ratio 2010-2024 | ABBV

Current and historical p/e ratio for AbbVie (ABBV) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. AbbVie PE ratio as of July 24, 2024 is 15.80.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

AbbVie PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-07-24 176.21 52.29
2024-03-31 178.73 $3.37 53.04
2023-12-31 150.66 $2.73 55.19
2023-09-30 143.49 $3.65 39.31
2023-06-30 128.27 $4.86 26.39
2023-03-31 150.36 $4.23 35.55
2022-12-31 151.01 $6.61 22.85
2022-09-30 124.18 $7.49 16.58
2022-06-30 140.40 $7.06 19.89
2022-03-31 147.29 $6.97 21.13
2021-12-31 121.74 $6.45 18.87
2021-09-30 95.84 $4.20 22.82
2021-06-30 98.98 $3.71 26.68
2021-03-31 93.95 $2.83 33.20
2020-12-31 91.95 $2.86 32.15
2020-09-30 74.15 $4.73 15.68
2020-06-30 82.13 $4.70 17.47
2020-03-31 62.83 $5.65 11.12
2019-12-31 72.05 $5.28 13.65
2019-09-30 60.74 $2.17 27.99
2019-06-30 57.46 $2.72 21.12
2019-03-31 62.84 $3.49 18.01
2018-12-31 70.99 $3.58 19.83
2018-09-30 72.07 $4.84 14.89
2018-06-30 69.90 $4.04 17.30
2018-03-31 70.67 $3.97 17.80
2017-12-31 71.69 $3.29 21.79
2017-09-30 65.42 $4.11 15.92
2017-06-30 52.91 $4.07 13.00
2017-03-31 47.08 $3.86 12.20
2016-12-31 44.77 $3.72 12.04
2016-09-30 44.68 $3.61 12.38
2016-06-30 43.47 $3.47 12.53
2015-12-31 40.75 $3.12 13.06
2015-09-30 37.07 $1.69 21.94
2015-06-30 45.45 $1.78 25.53
2015-03-31 39.27 $1.26 31.17
2014-12-31 43.56 $1.31 33.25
2016-03-31 39.73 $2.43 16.35
2014-09-30 38.16 $2.30 16.59
2014-06-30 37.00 $2.59 14.29
2014-03-31 33.40 $2.57 13.00
2013-12-31 34.04 $2.56 13.30
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $305.760B $54.318B
AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $834.732B 120.64
Novo Nordisk (NVO) Denmark $598.098B 45.96
Johnson & Johnson (JNJ) United States $366.658B 14.54
Merck (MRK) United States $315.030B 57.32
AstraZeneca (AZN) United Kingdom $245.469B 21.34
Novartis AG (NVS) Switzerland $220.139B 15.30
Pfizer (PFE) United States $167.164B 20.77
Sanofi (SNY) $127.725B 12.04
Innoviva (INVA) United States $1.113B 7.82